Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous and intravenous use. It prevents and treats thromboembolic disorders such as deep vein thrombosis and pulmonary embolism in surgical, cardiac and dialysis patients.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring EU‑quality compliance and reliable global distribution.

Ledraxen is a low molecular weight heparin used to manage and prevent venous thromboembolism.

Prevention of deep vein thrombosis (DVT) in surgical patients: reduces clot formation after orthopedic or abdominal surgery. Treatment of acute deep vein thrombosis: promotes clot resolution and prevents propagation. Prevention and treatment of pulmonary embolism: limits embolic events in at‑risk patients. Anticoagulation in acute coronary syndrome: decreases recurrent ischemic events. Anticoagulation during hemodialysis: maintains circuit patency while minimizing bleeding.

Enoxaparin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: erythema, pain, or bruising at the injection site. - Minor bleeding: epistaxis, gum bleeding, or easy bruising. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening internal bleeding. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop. - Allergic reactions: anaphylaxis, urticaria, or angioedema. - Spinal/epidural hematoma: bleeding in the spinal canal after neuraxial procedures.

When prescribing Ledraxen, clinicians should consider several safety precautions to minimize risk.

Renal impairment: adjust dose or avoid in severe renal failure. Bleeding risk: avoid in patients with active bleeding or recent major surgery. Concomitant anticoagulants: monitor closely when used with warfarin, antiplatelet agents, or thrombolytics. Pregnancy: use only if benefit outweighs risk (Category B). Elderly patients: monitor for accumulation and bleeding. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Enoxaparin can interact with other medicines, altering its anticoagulant effect.

Major Interactions (Avoid): - Concurrent use with full‑dose warfarin: increased risk of severe bleeding. - Combination with direct thrombin inhibitors (e.g., dabigatran): additive anticoagulation. - Use with systemic thrombolytics (e.g., alteplase): heightened hemorrhagic risk. - Co‑administration with high‑dose NSAIDs: potentiates bleeding. - Concurrent spinal/epidural anesthesia with enoxaparin: risk of spinal hematoma.

Moderate Interactions (Monitor Closely): - Low‑dose aspirin: may increase minor bleeding. - SSRIs: modest increase in bleeding tendency. - Heparin flushes during catheter use: additive anticoagulant effect. - Antibiotics affecting gut flora (e.g., ciprofloxacin): possible alteration of platelet function. - Vitamin K antagonists: monitor INR closely.